# US 2006/0154936 A1 · Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154936 A1
- Document ID: US20060154936A1
- Status: Published application
- Kind: A1
- Application number: 10/532,297
- Filed: 2003-10-20
- Published: 2006-07-13
- Earliest claimed: 2002-10-25
- Inventors: Joseph Lasky
- Web page: https://patentgrep.com/patent/US20060154936A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 10)

The method according to claim 10, wherein the pulmonary hypertension is selected from primary pulmonary hypertension or secondary pulmonary hypertension.

### Claim 3 (depends on 10)

The method according to claim 10 wherein a daily dose of 100 to 1000 mg of COMPOUND I of the formula I is administered to an adult human.

### Claim 4 (depends on 3)

The method according to claim 3 wherein the daily dose is administered for a period exceeding three months.

### Claim 5 (depends on 10)

The method according to claim 10 wherein the pulmonary hypertension is not caused or accompanied by pulmonary fibrosis.

### Claim 6 (depends on 10)

The method according to claim 10 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine of the formula I is in the form of a pharmaceutically acceptable acid addition salt.

### Claim 7 (depends on 6)

The method according to claim 6 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-( 3 -pyridyl )-2-pyrimidine-amine of the formula I is in the form of the monomethanesulfonate salt.

### Claim 8

A combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine (designated hereinafter as COMPOUND I) and (b) at least one compound selected from the group comprising calcium channel antagonists, anticoagulants, endothelin receptor blockers, angiotensin-converting enzyme inhibitors, diuretics, and phosphodiesterease inhibitors for the manufacture of a medicament for the treatment of pulmonary hypertension.

### Claim 9 (depends on 8)

The combination according to claim 8 wherein (b) is at least one compound selected from the group comprising nifedipine, diltiazem, enalapril prostacyclin, adenosine, inhaled nitric oxide, warfarin, digoxin, bosentan, Viagra, and norepinephrine.

### Claim 10

A method of treating humans suffering from pulmonary hypertension which comprises administering to a said human in need of such treatment a dose, effective against pulmonary hypertension, of N-15-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine of the formula I
or a pharmaceutically acceptable salt thereof.
